Status: Recruiting

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

This study is designed to establish the foundation for a new therapy for neurofibromatosis Type I (NF1)-related cutaneous neurofibromas (cNFs) by assessing the feasibility and efficacy of IMLYGIC in adults with NF1 and cNFs who desire local treatment of their cNF due to disfigurement, progression, pain, itching or other concerns. This is a single institutional Phase 1 study with a safety run-in to assess the feasibility and efficacy of IMLYGIC monotherapy in NF1 patients with cNFs. Each 28-day treatment cycle will be defined as intralesional administration of IMLYGIC administered on day 1 and 21 of Cycle 1 and days 7 and 21 for Cycles 2-4 for up to 4 cycles.

Participants needed: 10

Trial details

Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Johns Hopkins UniversityUpdated: May 8, 2026Locations: 1

Eligibility criteria

Males or females age ≥ 18 years who meet the NIH clinical criteria for the diagn... [+29]

Any underlying medical condition, which in the opinion of the investigator, woul... [+18]

Status: Recruiting

DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins

The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibroma, and normal tissue during surgery.

Participants needed: 60

Trial details

Age: 1+Biological sex: AllType: ObservationalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 9, 2026Locations: 1

Eligibility criteria

This study will enroll approximately 60 participants diagnosed with either MPNST... [+5]

Adult patients with cognitive impairment requiring a legally authorized represen... [+2]